Evofem's Hormone-Free Contraceptive PHEXXI Seeks UAE Approval
ByAinvest
Tuesday, Jun 24, 2025 7:30 pm ET1min read
EVCM--
Evofem Biosciences, Inc. (OTCPK: EVFM) announced that Pharma 1 Drug Store LLC has filed an application with the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) seeking approval for the commercialization of PHEXXI, Evofem's FDA-approved hormone-free contraceptive [1]. The application marks a significant milestone in Evofem's global expansion strategy.
PHEXXI, the first and only locally-acting contraceptive gel approved by the U.S. Food and Drug Administration (FDA), is applied zero-to-60 minutes before intercourse using a pre-filled applicator. It works by maintaining the normal vaginal microbiome with a pH inhospitable to sperm and certain pathogens [1].
Market research indicates growing demand for hormone-free, on-demand contraception in the UAE and the surrounding region. Pharma 1 plans to launch PHEXXI in the UAE in the first quarter of 2026, following regulatory approval [2]. Pharma 1 holds exclusive commercialization rights for PHEXXI in the Middle East, including the UAE, Kuwait, Saudi Arabia, Qatar, and certain other countries in the licensed region [1].
Evofem CEO Saundra Pelletier expressed optimism about the potential for PHEXXI in the UAE market, stating, "We look forward to expanding and diversifying our revenue stream with PHEXXI sales to Pharma 1 for the UAE beginning in July 2025..." [2].
Pharma 1 is responsible for obtaining and maintaining any regulatory approvals required to market and sell PHEXXI, and will handle all aspects of distribution, sales, and marketing in these countries [1].
References:
[1] https://www.prnewswire.com/news-releases/evofems-phexxi-submitted-for-marketing-approval-in-united-arab-emirates-by-pharma-1-drug-store-302487645.html
[2] https://www.nasdaq.com/articles/evofem-biosciences-says-pharma-1-applies-marketing-approval-phexxi-uae
Evofem Biosciences announced that Pharma 1 Drug Store LLC has filed an application with the UAE Ministry of Health and Prevention seeking approval for the commercialization of PHEXXI, Evofem's FDA-approved hormone-free contraceptive. Market research indicates growing demand for hormone-free, on-demand contraception in the UAE and surrounding region. Evofem plans to launch PHEXXI in the UAE as quickly as possible following approval.
Title: Pharma 1 Submits PHEXXI Marketing Application in the UAEEvofem Biosciences, Inc. (OTCPK: EVFM) announced that Pharma 1 Drug Store LLC has filed an application with the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) seeking approval for the commercialization of PHEXXI, Evofem's FDA-approved hormone-free contraceptive [1]. The application marks a significant milestone in Evofem's global expansion strategy.
PHEXXI, the first and only locally-acting contraceptive gel approved by the U.S. Food and Drug Administration (FDA), is applied zero-to-60 minutes before intercourse using a pre-filled applicator. It works by maintaining the normal vaginal microbiome with a pH inhospitable to sperm and certain pathogens [1].
Market research indicates growing demand for hormone-free, on-demand contraception in the UAE and the surrounding region. Pharma 1 plans to launch PHEXXI in the UAE in the first quarter of 2026, following regulatory approval [2]. Pharma 1 holds exclusive commercialization rights for PHEXXI in the Middle East, including the UAE, Kuwait, Saudi Arabia, Qatar, and certain other countries in the licensed region [1].
Evofem CEO Saundra Pelletier expressed optimism about the potential for PHEXXI in the UAE market, stating, "We look forward to expanding and diversifying our revenue stream with PHEXXI sales to Pharma 1 for the UAE beginning in July 2025..." [2].
Pharma 1 is responsible for obtaining and maintaining any regulatory approvals required to market and sell PHEXXI, and will handle all aspects of distribution, sales, and marketing in these countries [1].
References:
[1] https://www.prnewswire.com/news-releases/evofems-phexxi-submitted-for-marketing-approval-in-united-arab-emirates-by-pharma-1-drug-store-302487645.html
[2] https://www.nasdaq.com/articles/evofem-biosciences-says-pharma-1-applies-marketing-approval-phexxi-uae
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet